RACE: Marketing Blitz 2021-2022

Race Oncology kicked off a stack of trials In early CY2021 to confirm the efficacy and safety of its superior oncological drug, Zantrene, in the current regulatory regime and across a number of cancer indications. Race is also confident that Zantrene can act as an FTO inhibitor (based on independent research papers) which likely is a breakthrough method of operation (First in Class, Best in Class) in treating cancer potentially acting synergistically with other standard of care drugs.

Below shows how busy the management and BOD were in the last year (each announcement was a great stride!) in laying the solid groundwork to prove the drug's potential and as a result set the stage for a blockbuster buyout by Big Pharma (BP).



As the results of the below open-label trials start to come and provide the news flow, Race is starting off marketing efforts from the last quarter of CY2021 that are aimed at increasing investor and market awareness of the potential of Zantrene, and courting potential buyout deals from BP.


The first of such marketing efforts (my words, not official statement) is the below presentation by Phillip Lynch (CEO) and Dr.Daniel Tillet (CSO):



Register for the event here: https://www.irdepartment.com.au/site/ird-invest/technology/ird-invest-innovation-and-change

Post any further such events, news, media coverage etc on this thread.